Molecular imaging in tumor angiogenesis and relevant drug research

Area of Science:

• Oncology
• Medical Imaging
• Pharmacology

Background:

• Tumor angiogenesis and drug development is a lengthy, high-risk, and costly process requiring 10-15 years for FDA approval.
• Molecular imaging modalities offer critical insights into tumor mechanisms and drug efficacy.
• Accurate anatomical, functional, and optical information is crucial for effective tumor and drug research.

Purpose of the Study:

• To review the characteristics of various molecular imaging modalities.
• To explore the applications of molecular imaging in tumor angiogenesis research.
• To highlight the role of molecular imaging in accelerating relevant drug development.

Main Methods:

• Review of fluorescence imaging (FMI), bioluminescence imaging (BLI), positron emission tomography (PET), single-photon emission-computed tomography (SPECT), and computed tomography (CT).
• Analysis of how each modality provides anatomical, functional, or optical information for regions of interest (ROI).
• Examination of published research on molecular imaging applications in tumor angiogenesis and drug development.

Main Results:

• CT (especially Micro-CT) provides anatomical information.
• PET and SPECT offer functional insights.
• BLI and FMI deliver optical data, aiding in understanding tumor angiogenesis and drug response.

Conclusions:

• Molecular imaging significantly enhances tumor angiogenesis and drug development research.
• The combined use of different imaging modalities provides comprehensive data for better decision-making.
• Molecular imaging accelerates the understanding of tumor biology and drug activity, potentially reducing development timelines.